Methane

Methane

SCHEMBL3448558

C.CCOC(=O)c1cc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2-n2nc(C(F)(F)F)cc2C)cnc1OCC=S(=O)=O

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.38
ERBB2 P04626 1/20 0.38
MAPT P10636 3/20 0.35
SYK P43405 2/20 0.35
JAK2 O60674 3/20 0.34
JAK1 P23458 3/20 0.34
TYK2 P29597 3/20 0.34
JAK3 P52333 3/20 0.34
BRD4 O60885 1/20 0.34
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
NPSR1 Q6W5P4 2/20 0.33
MEN1 O00255 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPC1 O15118 1/20 0.33
TSHR P16473 1/20 0.33
FGFR1 P11362 2/20 0.33
XBP1 P17861 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3449151 0.88 P2RX3 (0.40) EGFRERBB2MAPTSYKJAK2
Methane SCHEMBL3449659 0.87 NPSR1 (0.37) MAPTSYKKMT2AKDM4EGAA
SCHEMBL3448556 0.87 MAPT (0.38) EGFRERBB2MAPTSYKJAK2
SCHEMBL3447786 0.86 EGFR (0.37) EGFRERBB2MAPTSYKJAK2
SCHEMBL3450642 0.86 EGFR (0.38) EGFRERBB2MAPTSYKJAK2
SCHEMBL3449999 0.85 AXL (0.42) EGFRERBB2SYKBRD4PAK1
SCHEMBL3451285 0.84 AXL (0.37) EGFRSYKGAASTK17AKCNN3
SCHEMBL3448528 0.84 EGFR (0.41) EGFRERBB2MAPTSYKJAK2
SCHEMBL3379025 0.84 SYK (0.38) EGFRSYKSTK17A
SCHEMBL3448702 0.83 SYK (0.44) EGFRERBB2MAPTSYKJAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD EGFR 2771/4885ERBB2 2537/4885MAPT 3947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.